Trial Profile
An Observational, real-world study of Ticagelor versus Clopidogrel in patients with Acute Coronary Syndrome from the SCAAR registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2016
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- 28 Dec 2016 New trial record
- 01 Nov 2016 Primary endpoint (Death or Stent thrombosis at 30 days) has not been met, according to the results in the Journal of the American College of Cardiology
- 01 Nov 2016 Results published in the Journal of the American College of Cardiology